{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:27:50Z","timestamp":1791912470676,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82471426"],"award-info":[{"award-number":["82471426"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82571592"],"award-info":[{"award-number":["82571592"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010120","name":"Huashan Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010120","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008750","name":"Shanghai Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC2023CRD007"],"award-info":[{"award-number":["SHDC2023CRD007"]}],"id":[{"id":"10.13039\/501100008750","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2022YFC3501305"],"award-info":[{"award-number":["2022YFC3501305"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2022YFC3501303"],"award-info":[{"award-number":["2022YFC3501303"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.neurot.2026.e00831","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:28:10Z","timestamp":1768566490000},"page":"e00831","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting pathogenic Th17.1 cells via JAK-STAT3 pathway: A novel approach with tofacitinib for refractory myasthenia gravis"],"prefix":"10.1016","volume":"23","author":[{"given":"Rui","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huahua","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Huan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingxian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yarong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoguo","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2026.e00831_bib1","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2026.e00831_bib2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2026.e00831_bib3","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211065406","article-title":"Advances and challenges in the treatment of myasthenia gravis","volume":"14","author":"Schneider-Gold","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.neurot.2026.e00831_bib4","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s00415-025-12922-7","article-title":"Myasthenia gravis in 2025: five new things and four hopes for the future","volume":"272","author":"Binks","year":"2025","journal-title":"J Neurol"},{"key":"10.1016\/j.neurot.2026.e00831_bib5","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41582-023-00916-w","article-title":"Myasthenia gravis: the changing treatment landscape in the era of molecular therapies","volume":"20","author":"Iorio","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurot.2026.e00831_bib6","doi-asserted-by":"crossref","DOI":"10.1177\/1756285617749134","article-title":"When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies","volume":"11","author":"Mantegazza","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.neurot.2026.e00831_bib7","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419832242","article-title":"Understanding the burden of refractory myasthenia gravis","volume":"12","author":"Schneider-Gold","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.neurot.2026.e00831_bib8","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213428","article-title":"Cost trends of new-to-market neurologic medications: an insurance claims database analysis","volume":"104","author":"Gusovsky Chevalier","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2026.e00831_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102800","article-title":"The role of innate immunity in myasthenia gravis","volume":"20","author":"Zhao","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.neurot.2026.e00831_bib10","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.4049\/jimmunol.1501339","article-title":"Autoreactive T cells from patients with myasthenia gravis are characterized by elevated IL-17, IFN-\u03b3, and GM-CSF and diminished IL-10 production","volume":"196","author":"Cao","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.neurot.2026.e00831_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108492","article-title":"Circulating Th1\/17 cells serve as a biomarker of disease severity and a target for early intervention in AChR-MG patients","volume":"218","author":"Ma","year":"2020","journal-title":"Clin Immunol"},{"key":"10.1016\/j.neurot.2026.e00831_bib12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1084\/jem.20130301","article-title":"Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids","volume":"211","author":"Ramesh","year":"2014","journal-title":"J Exp Med"},{"key":"10.1016\/j.neurot.2026.e00831_bib13","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000894","article-title":"Brain-homing CD4(+) T cells display glucocorticoid-resistant features in MS","volume":"7","author":"Koetzier","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurot.2026.e00831_bib14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.molimm.2021.02.011","article-title":"Imbalance of Th17 and tregs in thymoma May be a pathological mechanism of myasthenia gravis","volume":"133","author":"Chen","year":"2021","journal-title":"Mol Immunol"},{"key":"10.1016\/j.neurot.2026.e00831_bib15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/ni.1993","article-title":"Fate mapping of IL-17-producing T cells in inflammatory responses","volume":"12","author":"Hirota","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.neurot.2026.e00831_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109693","article-title":"JAK2 inhibitor ameliorates the progression of experimental autoimmune myasthenia gravis and balances Th17\/Treg cells via regulating the JAK2\/STAT3-AKT\/mTOR signaling pathway","volume":"115","author":"Lu","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.neurot.2026.e00831_bib17","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/mus.28348","article-title":"The JAK1\/3 inhibitor tofacitinib regulates Th cell profiles and humoral immune responses in myasthenia gravis","volume":"71","author":"Bi","year":"2025","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.neurot.2026.e00831_bib18","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2026.e00831_bib19","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2026.e00831_bib20","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurot.2026.e00831_bib21","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/acn3.51312","article-title":"In-depth peripheral CD4(+) T profile correlates with myasthenic crisis","volume":"8","author":"Huan","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurot.2026.e00831_bib22","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.neurot.2026.e00831_bib23","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2026.e00831_bib24","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","article-title":"Anti-CD19 CAR T cells for refractory myasthenia gravis","volume":"22","author":"Haghikia","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2026.e00831_bib25","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00281-019-00733-8","article-title":"The pathogenicity of Th17 cells in autoimmune diseases","volume":"41","author":"Yasuda","year":"2019","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.neurot.2026.e00831_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2023.578129","article-title":"Thymoma patients with or without myasthenia gravis have increased Th17 cells, IL-17 production and ICOS expression","volume":"381","author":"Cebi","year":"2023","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.neurot.2026.e00831_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109130","article-title":"Interleukin-6 cytokine: an overview of the immune regulation, immune dysregulation, and therapeutic approach","volume":"111","author":"Aliyu","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.neurot.2026.e00831_bib28","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","article-title":"Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.neurot.2026.e00831_bib29","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.medcli.2023.04.006","article-title":"Myasthenia gravis. Update on diagnosis and therapy","volume":"161","author":"Garc\u00eda Est\u00e9vez","year":"2023","journal-title":"Med Clin"},{"key":"10.1016\/j.neurot.2026.e00831_bib30","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/acn3.51492","article-title":"Drug-refractory myasthenia gravis: clinical characteristics, treatments, and outcome","volume":"9","author":"Cort\u00e9s-Vicente","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurot.2026.e00831_bib31","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1474-4422(24)00028-0","article-title":"Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study","volume":"23","author":"Narayanaswami","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2026.e00831_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci13091286","article-title":"Diagnosis and management of seronegative myasthenia gravis: lights and shadows","volume":"13","author":"Vinciguerra","year":"2023","journal-title":"Brain Sci"},{"key":"10.1016\/j.neurot.2026.e00831_bib33","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/annrheumdis-2019-216656","article-title":"Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"79","author":"Kerschbaumer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.neurot.2026.e00831_bib34","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.molimm.2018.11.015","article-title":"A role for Th1-like Th17 cells in the pathogenesis of inflammatory and autoimmune disorders","volume":"105","author":"Kamali","year":"2019","journal-title":"Mol Immunol"},{"key":"10.1016\/j.neurot.2026.e00831_bib35","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","article-title":"IL-17 and IL-17-producing cells in protection versus pathology","volume":"23","author":"Mills","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.neurot.2026.e00831_bib36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12974-023-02691-3","article-title":"Blocking interleukin-23 ameliorates neuromuscular and thymic defects in myasthenia gravis","volume":"20","author":"Villegas","year":"2023","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.neurot.2026.e00831_bib37","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.neurot.2026.e00831_bib38","doi-asserted-by":"crossref","first-page":"528","DOI":"10.4049\/jimmunol.1402990","article-title":"Polyfunctional, pathogenic CD161+ Th17 lineage cells are resistant to regulatory T cell-mediated suppression in the context of autoimmunity","volume":"195","author":"Basdeo","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.neurot.2026.e00831_bib39","article-title":"Chronic inflammation up-regulates P-gp in peripheral mononuclear blood cells via the STAT3\/Nf-\u03bab pathway in 2,4,6-trinitrobenzene sulfonic acid-induced colitis mice","volume":"5","author":"Liu","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurot.2026.e00831_bib40","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1134\/S0006297924604222","article-title":"Mechanisms of glucocorticoid resistance in nonclassical T helper populations Th17.1\/Ex-Th17","volume":"90","author":"Kuklina","year":"2025","journal-title":"Biochemistry (Mosc)"},{"key":"10.1016\/j.neurot.2026.e00831_bib41","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.immuni.2016.10.026","article-title":"GM-CSF: from growth factor to central mediator of tissue inflammation","volume":"45","author":"Becher","year":"2016","journal-title":"Immunity"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926000012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926000012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T07:48:53Z","timestamp":1778831333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926000012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1878747926000012"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00831","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting pathogenic Th17.1 cells via JAK-STAT3 pathway: A novel approach with tofacitinib for refractory myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00831","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00831"}}